Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 9/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.41 |
| ▸ | CDK2 | P24941 | 9/20 | 0.41 |
| ▸ | CDK4 | P11802 | 3/20 | 0.39 |
| ▸ | CCND1 | P24385 | 3/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1612079 | 0.72 | MAOA (0.51) | MAOAALDH1A1HPGDKDM4EGAA | |
| SCHEMBL1337358 | 0.70 | BAZ2B (0.49) | MAOAALDH1A1HPGDKDM4EGAA | |
| SCHEMBL24632112 | 0.70 | ALDH1A1 (0.55) | MAOAALDH1A1HPGDKDM4EGAA | |
| SCHEMBL4877329 | 0.70 | MAOA (0.49) | MAOAALDH1A1HPGDKDM4EGAA | |
| SCHEMBL4956575 | 0.69 | MAOA (0.59) | MAOAALDH1A1HPGDKDM4EGAA | |
| SCHEMBL1273609 | 0.68 | NPC1 (0.68) | MAOAALDH1A1HPGDKDM4EGAA | |
| SCHEMBL30002207 | 0.68 | NPC1 (0.68) | MAOAALDH1A1HPGDKDM4EGAA | |
| SCHEMBL22904136 | 0.68 | ALDH1A1 (0.60) | MAOAALDH1A1HPGDKDM4EGAA | |
| SCHEMBL9279689 | 0.68 | MAOA (0.66) | MAOAALDH1A1HPGDKDM4EGAA | |
| SCHEMBL20334273 | 0.67 | MAOA (0.90) | MAOAALDH1A1HPGDKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10624882-B2 | Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20180344723-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2018-12-06 | — | — | US | disclosed |
| US-20160243102-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2016-08-25 | — | — | US | disclosed |
| US-20150297581-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2015-10-22 | — | — | US | disclosed |
| US-20140357652-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2014-12-04 | — | — | US | disclosed |
| US-8809326-B2 | Isoquinolinone Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2068878-A2 | RHO KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-06-17 | — | — | EP | disclosed |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ALCON INC. (CH) | 2008-07-03 | — | — | US | disclosed |
| WO-2008036540-A2 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243102-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | MAOA 1250/4885ALDH1A1 4263/4885HPGD 630/4885 |
| US-20150297581-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | MAOA 1250/4885ALDH1A1 4263/4885HPGD 630/4885 |
| US-10624882-B2 | Rho kinase inhibitors | ROCK1, ROCK2, CIT | MAOA 1250/4885ALDH1A1 4263/4885HPGD 630/4885 |
| US-20140357652-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | MAOA 1250/4885ALDH1A1 4263/4885HPGD 630/4885 |
| US-20180344723-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | MAOA 1250/4885ALDH1A1 4263/4885HPGD 630/4885 |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ROCK1, ROCK2, ARHGDIA | MAOA 1495/4885ALDH1A1 2595/4885HPGD 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.